- Home
- CNF vs SBFM Comparison
CNF vs SBFM Comparison
Compare CNF & SBFM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CNF | SBFM |
|---|---|---|
| Founded | 1999 | 2006 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.0M | 7.2M |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | CNF | SBFM |
|---|---|---|
| Price | $6.21 | $1.27 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 8.4K | ★ 48.1K |
| Earning Date | 08-28-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $50,241,013.00 | $37,323,742.00 |
| Revenue This Year | $252.34 | $10.26 |
| Revenue Next Year | N/A | $32.63 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 13.24 |
| 52 Week Low | $2.36 | $1.16 |
| 52 Week High | $13.90 | $3.90 |
Technical Indicators
Market Signals| Indicator | CNF | SBFM |
|---|---|---|
| Relative Strength Index (RSI) | 62.46 | 30.51 |
| Support Level | $5.90 | $1.16 |
| Resistance Level | $6.20 | $1.40 |
| Average True Range (ATR) | 0.17 | 0.08 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 98.36 | 28.42 |
Price Performance
Historical ComparisonAbout CNF CNFinance Holdings Limited each representing twenty (20)
CNFinance Holdings Ltd is an equity loan service provider. It focuses on the development of small and micro-enterprises. It generates revenue in the form of interest and financing service fees on loans and interest on deposits with banks. Its primary target borrower segment is MSE owners who own real properties in Tier 1 and Tier 2 cities in China. Geographically, it has an operation in PRC.
About SBFM Sunshine Biopharma Inc.
Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. Through its subsidiaries, the company has various generic prescription drugs on the market in Canada and is also involved in developing and selling OTC supplements. In addition, the company is conducting a proprietary drug development program, which is comprised of K1.1 mRNA targeted for liver cancer and SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections.